scholarly journals Nephrogenic diabetes insipidus caused by mutation of Tyr205: A key residue of V2 vasopressin receptor function

2005 ◽  
Vol 25 (5) ◽  
pp. 505-505 ◽  
Author(s):  
Katrin Sangkuhl ◽  
Holger Römpler ◽  
Wibke Busch ◽  
Beate Karges ◽  
Torsten Schöneberg
Keyword(s):  
Diabetes Insipidus ◽  
Nephrogenic Diabetes Insipidus ◽  
Vasopressin Receptor ◽  
Receptor Function ◽  
V2 Vasopressin Receptor

scholarly journals V2 Vasopressin Receptor (V2R) Mutations in Partial Nephrogenic Diabetes Insipidus Highlight Protean Agonism of V2R Antagonists

2011 ◽  
Vol 287 (3) ◽  
pp. 2099-2106 ◽  
Author(s):  
Kazuhiro Takahashi ◽  
Noriko Makita ◽  
Katsunori Manaka ◽  
Masataka Hisano ◽  
Yuko Akioka ◽  
...  
Keyword(s):  
Diabetes Insipidus ◽  
Nephrogenic Diabetes Insipidus ◽  
Vasopressin Receptor ◽  
V2 Vasopressin Receptor

Functional Rescue of the Constitutively Internalized V2 Vasopressin Receptor Mutant R137H by the Pharmacological Chaperone Action of SR49059

2004 ◽  
Vol 18 (8) ◽  
pp. 2074-2084 ◽  
Author(s):  
Virginie Bernier ◽  
Monique Lagacé ◽  
Michèle Lonergan ◽  
Marie-Françoise Arthus ◽  
Daniel G. Bichet ◽  
...  
Keyword(s):  
Cell Surface ◽  
Diabetes Insipidus ◽  
Nephrogenic Diabetes Insipidus ◽  
Vasopressin Receptor ◽  
Metabolic Labeling ◽  
Pharmacological Chaperone ◽  
Pharmacological Chaperones ◽  
Receptor Mutant ◽  
V2 Vasopressin Receptor ◽  
And Function

Abstract In most cases, nephrogenic diabetes insipidus results from mutations in the V2 vasopressin receptor (V2R) gene that cause intracellular retention of improperly folded receptors. We previously reported that cell permeable V2R antagonists act as pharmacological chaperones that rescue folding, trafficking, and function of several V2R mutants. More recently, the vasopressin antagonist, SR49059, was found to be therapeutically active in nephrogenic diabetes insipidus patients. Three of the patients with positive responses harbored the mutation R137H, previously reported to lead to constitutive endocytosis. This raises the possibility that, instead of acting as a pharmacological chaperone by favoring proper maturation of the receptors, SR49059 could mediate its action on R137H V2R by preventing its endocytosis. Here we report that the β-arrestin-mediated constitutive endocytosis of R137H V2R is not affected by SR49059, indicating that the functional rescue observed does not result from a stabilization of the receptor at the cell surface. Moreover, metabolic labeling revealed that R137H V2R is also poorly processed to the mature form. SR49059 treatment significantly improved its maturation and cell surface targeting, indicating that the functional rescue of R137H V2Rs results from the pharmacological chaperone action of the antagonist.

scholarly journals A Novel V2 Vasopressin Receptor Mutation with X-Linked Nephrogenic Diabetes Insipidus

2006 ◽  
Vol 15 (1) ◽  
pp. 41-43 ◽  
Author(s):  
Takayuki Okamoto ◽  
Norio Kobayashi ◽  
Hiroyuki Naito ◽  
Toshihiro Tajima
Keyword(s):  
Diabetes Insipidus ◽  
Nephrogenic Diabetes Insipidus ◽  
Vasopressin Receptor ◽  
V2 Vasopressin Receptor
Sign in / Sign up

Export Citation Format

Share Document